These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21965474)

  • 41. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
    Ross KS; Carter HB; Pearson JD; Guess HA
    JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
    Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
    J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001.
    Sarma AV; Schottenfeld D
    Semin Urol Oncol; 2002 Feb; 20(1):3-9. PubMed ID: 11828352
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
    Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
    Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interpreting recent trends in prostate cancer incidence and mortality.
    Gann PH
    Epidemiology; 1997 Mar; 8(2):117-20. PubMed ID: 9229198
    [No Abstract]   [Full Text] [Related]  

  • 46. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
    PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Temporal trends in cause of death among Swedish and US men with prostate cancer.
    Epstein MM; Edgren G; Rider JR; Mucci LA; Adami HO
    J Natl Cancer Inst; 2012 Sep; 104(17):1335-42. PubMed ID: 22835388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.
    Howrey BT; Kuo YF; Lin YL; Goodwin JS
    J Gerontol A Biol Sci Med Sci; 2013 Jan; 68(1):56-61. PubMed ID: 22562961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
    Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
    Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
    Etzioni R; Gulati R; Falcon S; Penson DF
    Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prostate cancer mortality in areas with high and low prostate cancer incidence.
    Stattin P; Carlsson S; Holmström B; Vickers A; Hugosson J; Lilja H; Jonsson H
    J Natl Cancer Inst; 2014 Mar; 106(3):dju007. PubMed ID: 24610909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database.
    Stephenson RA
    Urol Clin North Am; 2002 Feb; 29(1):173-81. PubMed ID: 12109343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California.
    Cheng I; Witte JS; McClure LA; Shema SJ; Cockburn MG; John EM; Clarke CA
    Cancer Causes Control; 2009 Oct; 20(8):1431-40. PubMed ID: 19526319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    Gulati R; Psutka SP; Etzioni R
    J Urol; 2019 Nov; 202(5):936-943. PubMed ID: 31112106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Descriptive epidemiology of prostate cancer in Japan and Western countries].
    Wakai K
    Nihon Rinsho; 2005 Feb; 63(2):207-12. PubMed ID: 15714967
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
    Gulati R; Gore JL; Etzioni R
    Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
    Kaur D; Ulloa-Pérez E; Gulati R; Etzioni R
    Cancer; 2018 Apr; 124(8):1752-1759. PubMed ID: 29370459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials.
    Goodwin JS; Tan A; Jaramillo E; Kuo YF
    J Natl Cancer Inst; 2013 May; 105(10):743-5. PubMed ID: 23459245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.